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The uroplakins (UPs) are a family of proteins which associate
with each other and form plaques on the apical surface of the
urothelium. These plaques contribute to a permeability
barrier, preventing the influx of urine from the urinary tract
lumen. Urinary tract malformations associated with human
and mouse UP mutations, the human fetal expression
patterns of UPs and experiments in Xenopus oocytes are
collectively revealing new functions for the UPs, forcing us to
view these proteins in a new light. Rather than simply being
products of the urothelial differentiation program, they may
be a group of proteins central to the process of urinary tract
differentiation itself.
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The extreme ‘kidney-centric’ perspective of the lower urinary
tract (i.e. the renal pelvis, ureter, bladder, and urethra) is that
it simply represents a ‘drain’ through which urine flows. This
conduit, however, assumes a much greater clinical impor-
tance in the context of human congenital malformations
because both kidney and lower urinary tract anomalies often
coexist: as examples, renal agenesis is often accompanied by
absent ureters; hypoplastic (too few nephrons) and dysplastic
(immature and metaplastic tissues) kidneys are often
attached to atretic, refluxing or duplicated ureters; and, in
boys, malformed kidneys commonly occur with urethral
valves.1 In these scenarios, the practices of Nephrology and
Urology naturally must be integrated to consider the whole
urinary tract as a single entity.
Matching the clinical imperatives of caring for individuals
in whom urinary tract development has gone wrong, there is
a rich history in which investigators have considered the
causes of such human aberrations, beginning with anatomi-
cal observations,2–6 and then moving on to experimental in
vivo7–10 and ex vivo11–14 manipulations of the developing
urinary tract.
Some of the key anatomic observations have been: that
kidney, ureter, and bladder development are synchronized;
that the mesonephric duct not only gives rise to the ureteric
bud, which differentiates into the ureter, renal pelvis, and
collecting ducts, but also incorporates with the urogenital
sinus, the nascent bladder; that an abnormal trajectory of the
ureteric bud correlates with failure of the intermediate
mesoderm to form nephrons; and that experimental impair-
ment of fetal urine flow leads to dysmorphogenesis of both
the kidneys and bladder. In recent decades, these anatomical
observations have been complemented by biological studies,
which have again highlighted the harmony of upper and
lower urinary tract morphogenesis. As examples: basic
processes such as programmed cell death occur in normal
upper and lower urinary tract differentiation;10,15,16 and
certain molecular signalling systems, such as those mediated
by bone morphogenetic proteins and angiotensin II are
shared by upper and lower urinary tracts.17
It is in the above contexts that we here review the
uroplakin (UP) family of proteins in relation to normal and
abnormal urinary tract development, emphasizing lessons for
human congenital disease. The story, which incorporates cell,
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molecular and developmental biology, along with molecular
genetics, should leave one in little doubt that the lower
urinary tract is, indeed, rather more complex than tubing
through which urine flows.
THE ASYMMETRIC UNIT MEMBRANE AND THE UROPLAKINS
The urothelium is a pseudo-stratified epithelium lining the
urinary tract from renal pelvis to the bladder outlet.18 A
peculiar feature is that the luminal leaflet of the apical
membrane is twice as thick as the cytoplasmic leaflet,19
explaining why it is called the ‘asymmetric unit membrane’.
The asymmetric unit membrane is covered by a crystalline
2D array of protein particles arranged into hexagonal arrays
with a distance of 16 nm between the centers of each, forming
the ‘urothelial plaques’.20,21 These plaques are interspersed by
regions of membrane that are not asymmetric, called ‘hinge
regions’. By generating antibodies against crude fractions of
bovine asymmetric unit membrane, screening for those
which specifically labelled superficial urothelial cells (the
criterion originally used to assess specificity for UPs) and
affinity-purifying the detergent-soluble fraction using these
antibodies, five major products were isolated and their
complementary DNAs were characterized.22–26 These were
referred to as the ‘uroplakins’, that is, constituents of
urothelial plaques. UP-rich plaques are found in the most
superficial (i.e. facing the urinary tract lumen) urothelial
cells; these are called umbrella cells because of their flat and
broad shape.27
UP1a and UP1b (originally considered a single protein
species, ‘UPI’, as both are approximately 27 kDa)28 are
tetraspanins, having four transmembrane domains that split
the protein into one large and one small extracellular
domain. UPII (15 kDa), UPIIIa (47 kDa), and UPIIIb
(35 kDa) are type I, single-pass transmembrane proteins.
The transmembrane topology of the UPs21,24–26 accounts for
the ‘asymmetry’ of the asymmetric unit membrane because,
whereas all UPs have large extracellular domains, only UPIIIa
and UPIIIb have significant cytoplasmic domains of 52 and
49 amino acids, respectively. Six UP1a/UPII/UP1b/UPIIIa
heterotetramers make up each 16 nm particle,21 although, in
a subset, UPIIIb is substituted for UPIIIa.23
The identification of the UPs, and the generation of
antibodies that specifically recognize them, facilitated ex-
ploration of the biophysical relationships within this group of
proteins. UPs form specific UP1a/UPII and UP1b/UPIII(a/b)
heterodimers,29 a prerequisite for their normal escape from
the endoplasmic reticulum and subsequent transport to the
cell surface.23,30 Indeed, in UPII or UPIIIa null-mutant mice,
there exists disrupted intracellular transport of only the
heterodimeric partner of the particular protein encoded by
each mutant gene, whereas all other UPs are localized
normally at the cell surface; plaque formation is also
disrupted.31,32 The UPs are glycosylated proteins, and their
luminal sugar moieties are modified as they pass along the
secretory pathway; the pro-sequence of UPII is cleaved in the
Golgi apparatus by furins.28 UP1b is the only UP that can exit
the endoplasmic reticulum of its own accord,30 although in
UPIIIa null-mutant mice it is mistargeted to the basolateral
membrane and its sugars are incompletely processed.31 By
facilitating escape from the endoplasmic reticulum, and thus
avoiding proteasomal degradation, UP1a and UP1b effectively
stabilize their partners, a general property of tetraspanins.28
Urothelial cells possess ‘molecular machinery’ that regu-
lates UP processing and transport, and this includes Rab27b,
a protein characteristic of differentiated urothelial cells and
which colocalizes with UPIIIa directly below the apical
membrane.33 UPs appear to be delivered to the apical
urothelial membrane in association with discoidal vesicles,
with enhanced delivery to (and removal from) the apical
membrane occurring in the urinary bladder as it stretches
and fills: in this context, it has been envisaged that UP
delivery allows formation of further plaques to cover an
increased surface area of urothelium.34
UROPLAKINS AS URINARY TRACT BARRIERS
Because descriptive studies had emphasized that UPs were
differentiation products of the urothelium,18 their possible
roles, especially as ‘barrier molecules’, were therefore initially
considered in the context of the mature, postnatal urinary
tract. Indeed, the ‘anti-permeability’ hypothesis was sup-
ported by Hu et al.31,35 who reported that the genetic ablation
of UPIIIa in mice not only diminished UP localization in
urothelial apical membranes and reduced plaque size but also
resulted in increased water and urea permeabilities across this
membrane; at the same time, tight junction barrier functions
were unaltered.
As described earlier, UPs contribute to the urothelial
glycocalyx, so they might, a priori, be considered to constitute
a physical barrier, which repels, and prevents the invasion of,
bacteria within the urinary lumen. It is therefore notable that
pathogenic, type 1 fimbriated Escherichia coli associate with
urothelial plasma membrane caveolae and lipid rafts, and
that UP1a, a lipid raft component, is a type 1 fimbrial
receptor.36 Furthermore, bacteria can ‘hide’ in superficial
urothelial cells, encased and perhaps even protected by UPs.37
As these insights were broadening our perception of the roles
for UPs in health and disease, the results of two key animal
studies,31,32 summarized here, were also consistent with roles
for these proteins during urinary tract morphogenesis.
UROPLAKINS IN MOUSE URINARY TRACT DEVELOPMENT
Hu et al.31 generated UPIIIa homozygous null-mutant mice
and reported hydronephrosis in young animals: this was
accompanied by abnormally wide orifices at the junction of
ureters and bladders, hence explaining the presence of
vesicoureteric reflux (VUR). A similar urinary tract pheno-
type was generated by genetic ablation of UPII in mice,32 a
maneuver which led to a complete absence of urinary plaques
and umbrella cells. In the same study, it was observed that
VUR did not explain all the instances of hydronephrosis and,
in some mutant UPII mice, there existed urinary flow
impairment associated with urothelial outgrowths in the
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distal ureter which appeared to occlude the ureteric lumen; in
fact, similar outgrowths were also reported in UPIIIa null
mice.32 Furthermore, certain litters of UPII mutants died
from renal excretory failure.
UROPLAKINS IN HUMAN URINARY TRACT DEVELOPMENT
These mouse studies led to the consideration of whether UP
genes (i.e. either mutations or polymorphisms) might be
implicated in human renal tract malformations. Direct
sequencing of UP genes failed to reveal mutations in 76
individuals with primary (i.e. not associated with bladder
outflow obstruction), non-syndromic (i.e. not part of a
congenital multiorgan syndrome) VUR, although the minor
allele of a polymorphism in UPIIIa, Pro154Ala, was found to
have a significantly elevated frequency in a group of 243
affected individuals when compared to a ‘normal control’
population.38 To explore the possible functional significance
of this polymorphism, we performed preliminary experi-
ments, expressing variant proteins in COS-1 cells (Figure 1).
After co-transfection of wild-type UPIIIa with UP1b, UPIIIa
was immunodetected on the surface of cells, as expected; after
complementary DNA encoding UPIIIa Pro154Ala was co-
transfected with UP1b, UPIIIa protein did not appear at the
cell membrane, but was retained within cells, giving some
credence to putative functional effects of this polymorphism.
In another population with primary VUR, however, analyses
by transmission-disequilibrium (a more ‘genetically robust’
methodology than simple association studies) of variants in
the promoter and coding regions of UPIIIa (called UPK3 in
that study) showed no significant linkage to VUR.39
In an attempt to find mutations with a major role in renal
tract developmental disorders, we turned the focus to
individuals with severe renal tract malformations. Three
UPIIIa heterozygous mutations were found in four patients
with bilateral renal aplasia/dysplasia, without an overt
obstruction to urine flow, and all four had severe chronic
renal failure.40 Interestingly, all four mutations appeared to
have arisen de novo, being absent in parental leukocyte DNA,
firstly confirming the contention that these genetic changes
were indeed pathogenic, and secondly providing an explana-
tion for the sporadic nature of disease in these families.
Before the advent of advances in dialysis and transplantation,
these children would most likely not have survived to pass on
their genes, thus emphasizing the potential importance of
these findings for genetic counseling in relation to future
generations. A follow-up study of a group of children with
non-obstructive renal hypoplasia/dysplasia identified a fifth
de novo mutation in an individual with unilateral multicystic
dysplastic kidney,41 a condition associated with ureteric
atresia.1,3 These studies clearly implicate UPIIIa in human
congenital disease, and are the first mutations found to cause
non-syndromic urinary tract malformations.
DO UROPLAKINS TRANSDUCE SIGNALS IN UROTHELIAL
CELLS?
UPII and UPIIIa have been immunolocalized in the normal
human fetus from 7 weeks gestation in the urogenital sinus
and renal pelvis,40,42 and this is the likely onset of UP
expression in human urothelium.43 Together with the human
genetic data, described above, these observations raise the
possibility that the UPs have a direct role to play in
development rather than simply being required for structural
integrity.
Recent studies of Xenopus egg fertilization have implicated
one of the UPs in signal transduction.44,45 Frog UPIIIa
(xUPIII) is expressed in the normal egg, ovary, urinary tract,
and kidney. On the surface of unfertilized eggs, xUPIII and
xUP1b associate with membrane rafts and, upon fertilization,
xUPIII is tyrosine phosphorylated on residue 249 in its
carboxy-terminal cytoplasmic domain, and this phospho-
rylation depends on c-Src. Strikingly, biochemical activation
and subsequent egg cleavage can be blocked by anti-xUPIII
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Figure 1 | Abnormal transport of Pro154Ala UPIIIa in COS-1 cells. UPIIIa immunocytochemistry in (a, c, e, and g) non-permeabilized and
(b, d, f, and h) permeabilized COS-1 cells transfected with: (a and b) wild-type UPIIIa alone; (c and d) wild-type UPIIIa and wild-type UP1b;
(e and f) 154Ala variant UPIIIa alone; (g and h) 154Ala variant UPIIIa and wild-type UP1b. (a and e) Neither variant of UPIIIa reached the
cell surface when transfected alone but both (b and f) were immunodetected (green) in a pattern reminiscent of endoplasmic reticulum in
permeabilized cells. When co-transfected with UP1b, wild-type UPIIIa reached the (c) cell surface and, in (d) permeabilized cells, was detected
in a Golgi-like pattern. The 154Ala variant UPIIIa was, however, not detected at the cell surface when co-transfected with (g) UP1b, although
it was present within cells in a pattern reminiscent of (h) the Golgi apparatus. Note that untransfected COS-1 cells do not express UPs. See
Jenkins et al.40 for detailed general methodology of transfection and immunostaining. Bar¼ 20 mm.
Kidney International (2007) 71, 195–200 197
D Jenkins and AS Woolf: Uroplakins and malformations r e v i e w
antibodies, consistent with the idea that xUPIII is a sperm
receptor. It was subsequently found that cathepsin B, a
protease, could biochemically activate frog eggs, inducing
phosphorylation of c-Src and xUPIII. Furthermore, cathepsin
B partially digests xUPIII, and a synthetic xUPIII peptide,
containing a potential proteolytic site, inhibits not only
cathepsin B-mediated proteolysis and tyrosine phosphoryla-
tion of xUPIII but also sperm-induced egg activation.
Therefore, as depicted in Figure 2, an initial sperm/xUPIII
interaction and limited xUPIII proteolysis by sperm protease
might be the initiating event in Xenopus oocyte activation.
What then are the implications of the frog story for the
genetics of human urinary tract malformations? Remarkably,
locations of altered amino acids coded by human UPIIIa
missense mutations correspond to key parts of xUPIII
involved in egg activation, supporting the possibility that
mammalian UPIIIa has similar roles in urothelia.
First, UPIIIa has a peptide in the extracellular domain and
including part of the transmembrane region which is highly
evolutionarily conserved (IDTWPGRRSGGMIV).41 The GRR
residues are the motif cleaved by frog sperm protease45 and
the missense mutation reported by Schonfelder et al.41 in a
child with multicystic dysplastic kidney would code for a
Gly202Asp substitution in the corresponding region of the
human mutant UPIIIa protein. Working on the hypothesis
that human UPIIIa might also transduce signals, perhaps
triggered by a putative urinary tract ligand/enzyme, the
hypothetical mutant Gly202Asp UPIIIa protein would fail to
be proteolytically cleaved.
Second, the recurrent, de novo missense mutation at a
cytosine-phosphate-guanosine dinucleotide reported by
Jenkins et al.40 in two children with renal adysplasia is
predicted to generate a mutant protein with a Pro273Leu
change in the cytoplasmic domain of human UPIIIa. This
residue is close to Tyr266, the human residue equivalent to
the xUPIII tyrosine, which becomes phosphorylated as a
prerequisite for egg activation. Residues 273–277 are actually
absent from xUPIII, suggesting that human Pro273 is not
directly involved in phosphorylation. Rather, the Pro273Leu
mutation may alter the conformation of the cytoplasmic
domain of UPIIIa by ablating a ‘proline-kink’, thus altering
the availability of Tyr266 for phosphorylation.
Another provocative insight into the role of UPs is
provided by a mouse model of autoimmunity, in which
postnatal hydronephrosis was associated with the presence of
UPIIIa antibodies which were deposited on urothelia which
appeared more-multilayered than normal.46 The hydrone-
phrosis and urothelial multilayering in this model recall
congenital phenotypes in UPII and UPIIIa null-mutant
mice.31,32 One interpretation of the autoimmune model
would be that that the hydronephrosis phenotype is directly
related to ‘inactivation’ of UPIIIa function, and this might be
considered the mammalian urinary tract equivalent of
antibody-mediated blockade of frog egg activation described
by Sakakibara et al.44 On the other hand, the autoimmune
hydronephrosis in mice is accompanied by marked periure-
teric inflammation, and this, rather than a defect in putative
UP signalling, might distort the ureter and contribute to
obstruction.
UNANSWERED QUESTIONS AND FUTURE PERSPECTIVES
How frequent are UP mutations in individuals with urinary
tract malformations?
Jenkins et al.40 identified UPIIIa mutations in almost one-
quarter of patients with renal adysplasia who were part of a
pediatric renal failure program in London, UK;40 only one
mutation in 170 children with unilateral or bilateral renal
hypodysplasia (drawn from Western and Eastern European
and Turkish clinics) was found by Schonfelder et al.41
Therefore, the frequency of UPIIIa mutations appear rather
variable depending on the population studied (and perhaps
the techniques used to seek mutations), and we suggest that
chances of finding a genetic change in UPIIIa may be
enhanced by complete sequencing of the gene in children
with urinary tract malformations associated with severe renal
failure (i.e. Stage V Chronic Renal Disease). Recently, a
mutation in UPII was found in another patient with VUR
and chronic renal failure from the same London patient
group; this was a frameshifted allele (L60fs68X); the genetic
change was also found in the index case’s mother who had
Figure 2 | Intracellular signalling by UPIIIa: from frog egg to
mammalian urothelium. From left to right of picture: as shown in
Xenopus oocyte fertilization studies,44,45 the binding of sperm to
full-length xUPIII induces its cleavage by cathepsin B in the so-called
conserved region (red box containing the ‘-GRR-’ motif). Cleaved
xUPIIIa then serves to phosphorylate the remaining full-length xUPIIIa
protein, in the cytoplasmic domain (yellow circled ‘P’), in a process
that also requires activation of c-Src (also by phosphorylation).
Phosphorylated xUPIIIa is required for Xenopus oocyte fertilization,
showing that this active form of the protein serves to transduce
extracellular cues into cells. Amino-acid changes which would result
from reported de novo missense UPIIIa mutations in children with
urinary tract malformations40,41 are indicated in green. These
mutations occur in regions of UPIIIa important for signal transduction
in frog eggs, suggesting that UPIIIa might have similar roles in human
urothelia. ‘Question marks’ (in blue) raise questions regarding
pathway components in urothelial cells, which might be equivalent
to frog egg activation pathways. Note the glycosylation sites
(gray circles) on the long, extracellular part of UPIIIa, and the
short, cytoplasmic part of UPIIIa, which becomes phorphorylated
in oocytes. Key: L, lumenal aspect of the membrane; C,
cytoplasmic aspect.
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normal renal ultrasonography, but it was absent in 150
healthy Caucasian control individuals.42 It is possible that
this heterozygous change is incompletely penetrant, as is
homozygous null mutation of UPII in mice.32 In future, it
will be interesting to analyze the UP gene family in larger
unbiased DNA collections from individuals with urinary tract
malformations (e.g. The United Kingdom Vesicoureteric
Reflux DNA Collection http://www.vur.org.uk) in relation to
variations in UP genes. This may reveal genotype–phenotype
correlations, offering further insight into the roles of the UPs
in development.
What are the functional consequences of UPIIIa mutations?
Despite the human genetic findings outlined above, no study
has investigated the precise effects of missense UPIIIa
mutations on UPIIIa function. Such studies might serve to
illuminate the mode of action of the different alleles,
potentially distinguishing dominant-negative effects from a
loss-of-function. In this respect, at least two strategies can be
envisaged. The first would be to study the biological effects,
such as barrier function, state of cell differentiation, and
UPIIIa phosphorylation status following the experimental
expression of UP variants in more realistic cell types,
especially human urothelia in culture.47 The second would
be to generate transgenic mice in which UP alleles are
replaced by variants coding for missense changes; specifically,
would such animals have clinically relevant urinary tract
malformations?
How do UP mutations perturb lower urinary tract
development?
With regard to mouse null-mutant studies, it remains unclear
precisely how a lack of either UPII or UPIIIa might lead to
this range of congenital lower urinary tract anomalies. One
theory would rely on the physical properties of UP proteins;
specifically, one could postulate that excessive ‘leakiness’ of
the nascent urothelium would allow fetal urine to access
surrounding tissues, and damage them. A non-exclusive,
alternative explanation would be that UPs act as signalling
molecules in the mammalian urinary tract (Figure 2),
analogous to the Xenopus oocyte paradigm. Although there
is no evidence that urine is needed for the expression of UPs
themselves,48 postnatal urine does contain cathepsin B49 and
perhaps similar proteases might be present in fetal urine
where they might partially cleave UPIIIa. In future, one
should seek partially cleaved UPIIIa in developing urinary
tracts and also establish whether UPIIIa is tyrosine phospho-
rylated at any stage of development. We postulate that UPIIIa
phosphorylations might somehow alter gene expression, and
that this would have an effect on the morphogenesis of
adjacent smooth muscle. Certainly, it is well-established that
molecules, such as sonic hedgehog, are released by the
urothelium and that epithelial–mesenchymal cross-talk
enhances smooth muscle growth and differentiation.50,51
Further studies on the specialized cell biology of embryonic
ureter growth14 should be encouraged.
How can we explain the association of kidney malformations
with UP mutations?
Reporter assays have identified elements of the UP promoters
that drive their expression specifically in urothelial cells.52–54
Indeed, UPs are not immunodetected within epithelia of the
developing human kidney itself,40,42 raising the possibility
that UP mutations perturb kidney development secondary to
structural and/or functional defects of the pelvis and/or
ureter. For example, anatomical fetal ureteric obstruction
probably occurs in embryonic renal tracts from UPII
homozygous null-mutant mice,32 and this could be a
paradigm for a similar situation when an ‘atretic’ ureter is
found attached to a multicystic dysplastic kidney, and this
was the renal phenotype observed in the patient carrying the
mutation reported by Schonfelder et al.41 An alternative
theory could be that UP mutations lead to ‘functional
obstruction’ of urine flow, a phenomenon documented in
experimental animals with anatomically patent urinary tracts
which are otherwise functionally defective, often with
dysmorphogenesis of ureteric muscle.51,55–58 According to
this idea, fetal ureteric myogenic contractions13,55 are critical
in driving urine from the developing kidney towards the
bladder, an especially important phenomenon because the
changing orientation of fetuses mean that they can not ‘rely
on’ hydrostatic pressure to move urine down the ureter. In
order to investigate this hypothesis, it would be worth
investigating the contractility of fetal ureters from UP mutant
mice, for example by using explanted embryonic ureters.13,14
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